OX40-OX40L interactions: a promising therapeutic target for allergic diseases?
Recent advances in understanding the cellular and molecular mechanisms of atopy have shed light on potential targets for the development of new therapies for allergic diseases. In this issue of the JCI, Seshasayee et al. provide direct in vivo evidence that OX40 has critical roles in allergic inflammation mediated by thymic stromal lymphopoietin (TSLP) (see the related article beginning on page 3868). Blockade of interactions between OX40 on Th2 cells and OX40 ligand (OX40L) on TSLP-activated DCs using an OX40L-specific monoclonal antibody, inhibited Th2 cell-mediated immune responses in both mouse and nonhuman primate models of allergic inflammation. The results point to potential therapeutic approaches to targeting the cellular and molecular mechanism underlying TSLP-mediated allergic inflammation.
Wang
Yui-Hsi
YH
Department of Immunology and Center of Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. yuiwang@mdanderson.org
Liu
Yong-Jun
YJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D006224:Cricetinae; D016207:Cytokines / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007073:Immunoglobulin E / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy / Q000235:genetics / Q000276:immunology; D008168:Lung / Q000276:immunology / Q000473:pathology; D008253:Macaca mulatta; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008822:Mice, Transgenic; D053278:OX40 Ligand / Q000037:antagonists & inhibitors* / Q000276:immunology; D053262:Receptors, OX40 / Q000276:immunology; D012867:Skin / Q000276:immunology / Q000473:pathology; D018418:Th2 Cells / Q000276:immunology* / Q000473:pathology; D000079424:Tumor Necrosis Factor Inhibitors; D048069:Tumor Necrosis Factors / Q000276:immunology; D000094632:Thymic Stromal Lymphopoietin
D000911:Antibodies, Monoclonal; D016207:Cytokines; D008562:Membrane Glycoproteins; D053278:OX40 Ligand; D053262:Receptors, OX40; C505716:TNFRSF4 protein, human; C089251:TNFSF4 protein, human; C505717:Tnfrsf4 protein, mouse; C504586:Tnfsf4 protein, mouse; D000079424:Tumor Necrosis Factor Inhibitors; D048069:Tumor Necrosis Factors; D007073:Immunoglobulin E; D000094632:Thymic Stromal Lymphopoietin